participants. Pre-and postintervention surveys were conducted to assess the needs of the population and the overall satisfaction with the program. Results: The pilot program took place on May 18, 2015. Target enrollment was 30 patients and caregivers; 30 people registered and 28 attended (15 men, 13 women; 20 survivors, 8 caregivers). Most of the HNC survivors were >2 years from diagnosis and >1 year from their last cancer treatment. The key components of the program included (1) motivational welcome by physician staff; (2) physical activity programs including gentle yoga, NEAT (non-exercise activity thermogenesis), and a physical therapy session entitled "Open & Release Your Neck & Shoulders"; (3) resiliency participatory group sessions for both survivors and caregivers; and (4) a hands-on nutrition/cooking session demonstrating strategies to increase consumption of vegetables and fruits by making whole food smoothies and soup. Twenty-one participants responded to the preintervention survey. The top 2 reasons for participation were to improve overall health and increase energy. Other common reasons included to increase strength, increase flexibility, improve quality of life or longevity, and reduce weight or improve body composition. Twenty-six of the 28 participants responded to the postintervention survey. Sixty-one percent and 33% of patients were very satisfied and satisfied, respectively, and 1 person (6%) was neutral. Eighty-eight percent and 12% of caregivers were very satisfied and satisfied, respectively. No participants were dissatisfied. On the postintervention survey, the following components were rated most valuable: gentle yoga, NEAT, and the nutrition session. Physician referral was cited as an important motivator to participation. Conclusion: A comprehensive HNC-specific wellness intervention is feasible in this underserved patient population, and further programs for HNC patients should be developed.
OBJECTIVES: Iron chelators (deferasirox or desferrioxamine) are essential to patients who need life-long blood transfusion (e.g. -Thalassemia). However, in 2010, the US Food and Drug Administration (FDA) had issued a warning on potential adverse events associated with iron chelators, especially deferasirox. The objective of this retrospective cohort study was to compare the risk of renal impairment, hepatic impairment, and gastrointestinal bleeding in patients with transfusiondependent anemia using deferasirox or desferrioxamine. METHODS: Patients with transfusion-dependent anemia (sickle cell disease, -thalassaemia, myelodysplastic syndrome and aplastic anemia) and were prescribed iron chelators (deferasirox or desferrioxamine) were identified from the 2005Ϫ2009 Taiwan's National Health Insurance database. Cox proportional hazards models were used to assess the association between iron chelators and occurrences of adverse events (renal impairment, hepatic impairment, and gastrointestinal bleeding). All models adjusted for age, sex, drug exposure (days), type of transfusion-dependent anemia and medical history. RESULTS: Patients were categorized into deferasirox (nϭ180), desferrioxamine (nϭ586),and mixed users (nϭ202), based on the drug they received during the follow-up. The crude rates of adverse events were 4.14, 3.16 and 0.65 per 10,000 person-year in deferasirox, desferrioxamine and mix users, respectively. After adjusting covariates, there was no association between deferasirox and adverse events (hazard ratio [HR]0.84; 95% CI, 0.59 -2.00) compared to desferrioxamine users. CONCLUSIONS: In this population-based analysis, transfusion-dependant anemia patients using deferasirox and desferrioxamine were at similar risk of adverse events. OBJECTIVES:We examined proportions of patients: a) monitored for TIO after receiving Ն10, Ն20, and Ն30 units of red blood cells (RBC) and b) receiving iron chelation therapy (ICT). We also examined overall survival (OS) among: a) monitored vs. unmonitored; b) ICT-treated vs. ICT-untreated groups. METHODS: Medical records of patients Ͼ18 years receiving Ն10 RBC units Ն6 months before data abstraction were identified at ). Observation period spanned from 10th RBC unit to end of follow-up (i.e., death, clinic departure, or end of observation period). TIO moni-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.